Whitepaper: Pharmaceutical Industry Challenges Facing Clinical Trial Disclosure and Transparency

By MMS Holdings and TrialAssure

While global regulatory authorities routinely update clinical trial disclosure and transparency requirements, new regulations set to take effect in 2020 and 2021 will dramatically change how sponsors report clinical trial data.

Overall, the current regulations in both the EU/European Economic Area (EEA) and the US require the registration of new clinical trials and the posting of summary results for all completed studies, regardless of the approval status of the medicinal products.

The EU/EEA also requires the release of clinical reports and patient-level-data for trials approved, rejected, or withdrawn medicinal products. The US requires the study protocol, statistical analysis plan, and all amendments to be posted at the time study summary results are posted to ClinicalTrials.gov.

With these current practices in mind, it is important to review several challenges facing clinical trial sponsors in regard to clinical trial disclosure and transparency activities by region.

Fill out the form below to access the whitepaper.




Read On

Start plain language summaries early or get left behind - MMS Holdings

In July 2019, the European Union (EU) Clinical Trial Regulation No. 536/2014 will go into effect,...

Together Trial with EDC Database Designed by MMS Wins Trial of the Year

CANTON, Mich. (8/16/2022) – The TOGETHER Trial, which uses an Electronic Data Capture (EDC) system...

How does the European Union Clinical Trial Information System (EU-CTIS) Affect Clinical Trial Transparency?

By: Aaron Burr, Ph.D., Senior Medical Writer, Jennica Young, Ph.D., Clinical Trial Transparency...